Acute kidney injury Market: Epidemiology, Therapies, Companies, DelveInsight | Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therap

Acute kidney injury emerging therapies, such as RBT-1, OCE-205, and others, are expected to boost the Acute kidney injury Market in the upcoming years.

DelveInsight has launched a new report on "Acute kidney injury - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Acute kidney injury, historical and forecasted epidemiology as well as the Acute kidney injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Acute kidney injury market report @ https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Acute kidney injury Market Report:

Currently, there are no specific pharmacological treatments approved for Acute Kidney Injury (AKI). The AKI therapeutic market is primarily driven by the use of Renal Replacement Therapy (RRT) and off-label drugs, including classes such as ACE inhibitors, ARBs, diuretics, and NSAIDs.
The incidence of Acute Kidney Injury is increasing, especially among individuals with acute illnesses and those undergoing major surgical procedures.
In 2022, the total number of mortality-adjusted incident cases of AKI among hospitalized patients in the 7MM (seven major markets) was approximately 14.6 million.
The market for AKI treatment was largest in the United States in 2022, representing around 65% of the total market in the 7MM, and is expected to continue growing by 2034.
In February 2024, SeaStar Medical announced the enrollment of patients in the NEUTRALIZE-Acute Kidney Injury clinical trials of its cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy. This device aims to modulate the immune system to reduce inflammation and prevent kidney damage in critically ill adults with AKI requiring continuous kidney replacement therapy (CKRT) .
In February 2024, CalciMedica received FDA clearance for a Phase 2 trial of AuxoraTM in treating severe AKI associated with acute hypoxemic respiratory failure. AuxoraTM is a selective inhibitor of Orai1-mediated calcium release-activated calcium (CRAC) channels, targeting inflammation and cell death pathways implicated in AKI .
In December 2023, SeaStar Medical announced the start of patient enrollment in the NEUTRALIZE-Acute Kidney Injury clinical trials for its cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy, aimed at critically ill adults with AKI who require continuous kidney replacement therapy (CKRT).
In October 2023, Renibus Therapeutics revealed that the first patient had been treated in the pivotal Phase III PROTECT trial of RBT-1 for patients with post-operative complications from cardiac surgery. Top-line results are expected by mid-2025, with the New Drug Application (NDA) filing anticipated in early 2026.
In 2022, the total mortality-adjusted incident cases of Acute Kidney Injury in the United States were approximately 5.7 million. The US represented the largest share of incident cases, accounting for around 39% of the total in the 7MM.
The total Acute Kidney Injury (AKI) market size across the 7MM was approximately USD 6,230 million in 2022 and is expected to expand during the forecast period from 2024 to 2034. Estimates suggest that the United States had the largest AKI market size in 2022, with a projected compound annual growth rate (CAGR) of 4.1%.
Key Acute kidney injury companies such as Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others are evaluating new drugs for Acute kidney injury to improve the treatment landscape.
Promising Acute kidney injury therapies include RBT-1, OCE-205, and others.

Acute kidney injury Overview

Acute Kidney Injury is typically characterized by a sudden decline in kidney function, which is clinically identified by a temporary increase in nitrogen waste products, such as blood urea nitrogen (BUN) and serum creatinine levels, occurring over a period of hours to weeks. Common signs and symptoms of Acute Kidney Injury include nausea, vomiting, weakness, dizziness, and lower back pain. Some patients may show no symptoms, while others may experience general, non-specific symptoms that are not unique to kidney issues.

Acute kidney injury Market Outlook

A strong pipeline with innovative mechanisms of action, coupled with the rising incidence of Acute Kidney Injury (AKI), are key drivers for the AKI therapeutics market. The pipeline is expected to reshape the market dynamics, which currently consists primarily of biologics and drugs with novel mechanisms of action. At present, no targeted pharmacotherapies have been approved for AKI. The therapeutic market is largely driven by the use of Renal Replacement Therapy (RRT) and off-label drugs, including ACE inhibitors, ARBs, diuretics, and NSAIDs.

Comorbidities such as cardiovascular disease, hypertension, diabetes, pre-existing chronic kidney disease (CKD), and renal recovery complications increase the risk of AKI in patients. As noted, the current market is heavily reliant on RRT and conventional therapies like NSAIDs, ACE inhibitors, ARBs, and diuretics. However, this is likely to change as emerging therapies targeting AKI linked to comorbid conditions such as sepsis, cardiac surgery, and delayed graft function move through the pipeline. The AKI pipeline includes novel treatments aimed at conditions like HRS-AKI, post-cardiac surgery AKI, and sepsis-induced AKI, offering new options that could address the unmet need in AKI management. Key players in the emerging pipeline include Renibus Therapeutics (RBT-1), Ocelot Bio (OCE-205), AM-Pharma (Ilofotase alfa), and Guard Therapeutics (RMC-035), all of which are developing therapies to reduce mortality rates and improve outcomes in hospital settings. Overall, the AKI therapeutics market is projected to grow significantly during the forecast period from 2024 to 2034.

Discover how the Acute kidney injury market is rising in the coming years @ https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute kidney injury Emerging Drugs
RBT-1: Renibus Therapeutics
OCE-205: Ocelot Bio

Scope of the Acute kidney injury Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute kidney injury Companies: Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others
Key Acute kidney injury Therapies: RBT-1, OCE-205, and others
Acute kidney injury Therapeutic Assessment: Acute kidney injury current marketed and Acute kidney injury emerging therapies
Acute kidney injury Market Dynamics: Acute kidney injury market drivers and Acute kidney injury market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Acute kidney injury Unmet Needs, KOL's views, Analyst's views, Acute kidney injury Market Access and Reimbursement

To know what's more in our Acute kidney injury report, visit https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Acute kidney injury Market Report:
Acute kidney injury market report covers a descriptive overview and comprehensive insight of the Acute kidney injury Epidemiology and Acute kidney injury market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Acute kidney injury market report provides insights into the current and emerging therapies.
The Acute kidney injury market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Acute kidney injury market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute kidney injury market.

Got queries? Click here to know more about the Acute kidney injury market Landscape https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Acute kidney injury Patient Share (%) Overview at a Glance
5. Acute kidney injury Market Overview at a Glance
6. Acute kidney injury Disease Background and Overview
7. Acute kidney injury Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute kidney injury
9. Acute kidney injury Current Treatment and Medical Practices
10. Unmet Needs
11. Acute kidney injury Emerging Therapies
12. Acute kidney injury Market Outlook
13. Country-Wise Acute kidney injury Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Acute kidney injury Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Acute kidney injury Market Outlook 2034 https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Acute kidney injury Pipeline Insights, DelveInsight

"Acute kidney injury Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute kidney injury market. A detailed picture of the Acute kidney injury pipeline landscape is provided, which includes the disease overview and Acute kidney injury treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.